Efficacy and safety of initial combination treatment with sitagliptin and pioglitazone—a factorial study
暂无分享,去创建一个
R. Henry | V. Fonseca | B. Staels | G. Golm | K. Kaufman | R. B. Langdon | H. Steinberg | M. Chou | R. Teng | B. J. Goldstein
[1] A. Dobs,et al. Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo‐controlled 54‐week trial in patients with type 2 diabetes (一项为期54周的对持续使用二甲双胍与罗格列酮联合治疗的2型糖尿病患者加用西格列汀治疗的有效性与安全性的随机安慰剂对照研究) * , 2013, Journal of diabetes.
[2] M. Wright,et al. Examining the safety of PPAR agonists – current trends and future prospects , 2013, Expert opinion on drug safety.
[3] S. Inzucchi,et al. Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2013, Diabetologia.
[4] B. Staels,et al. Thiazolidinediones and PPARγ agonists: time for a reassessment , 2012, Trends in Endocrinology & Metabolism.
[5] D. Matthews,et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach , 2012, Diabetes Care.
[6] R. Gomis,et al. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double‐blind, placebo‐controlled study , 2011, Diabetes, obesity & metabolism.
[7] G. Golm,et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase‐4 inhibitor, and pioglitazone on glycemic control and measures of β‐cell function in patients with type 2 diabetes , 2011, International journal of clinical practice.
[8] J. Rosenstock,et al. Initial Combination Therapy With Alogliptin and Pioglitazone in Drug-Naïve Patients With Type 2 Diabetes , 2010, Diabetes Care.
[9] S. Mudaliar,et al. Pioglitazone: side effect and safety profile , 2010, Expert opinion on drug safety.
[10] R. Stolk,et al. Clinical inertia in general practice: widespread and related to the outcome of diabetes care. , 2009, Family practice.
[11] S. Marinopoulos,et al. Factors Associated With Intensification of Oral Diabetes Medications in Primary Care Provider-Patient Dyads: A Cohort Study , 2009, Diabetes Care.
[12] J. Rosenstock,et al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes , 2007, Diabetes, obesity & metabolism.
[13] Ronald Brazg,et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. , 2006, Clinical therapeutics.
[14] M. Burnier,et al. Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men. , 2004, The Journal of clinical endocrinology and metabolism.
[15] R. Turner,et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.